Question
stringlengths 13
1.05k
⌀ | Answer
stringlengths 2
801
⌀ |
---|---|
What should be used for computerized systems that contain any data that are relied on by an applicant in support of a marketing application?
|
principles outlined in this guidance
|
What is an example of a recorded source data transmitted from automated instruments directly to a computerized system?
|
chemistry autoanalyser
|
What is the purpose of the company's testing related to sterility and degradation?
|
g. Note that the company’s testing related to sterility and 337 degradation would primarily be intended to verify that the new process did not create 338 issues. the company’s testing related to sterility and 337 degradation
|
What does the guidance not apply to?
|
computerized medical devices that generate such data and that are otherwise regulated by FDA
|
What is IDE?
|
Notice of Claimed Investigational Exemption for a New Animal Drug
|
What is an example of a standard operating procedure that should be in place when using computerized systems to create, modify, maintain, or transmit electronic records?
|
inadvertently unblinding a study
|
What should be made available for use by personnel and for inspection by FDA?
|
SOPs
|
What is the requirement for source document retention?
|
retention of the original source document, or a copy of the source document
|
What should be maintained at another location?
|
a copy of the data
|
What should the system be designed to limit?
|
the number of log-in attempts
|
What should be changed at established intervals commensurate with a documented risk assessment?
|
passwords or other access keys
|
What is an example of a security measure that can prevent data entry until a password is entered?
|
an automatic screen saver
|
What can be used to verify the quality and integrity of data?
|
Computer-generated, time-stamped audit trails or other security measures
|
What is the tissue 349 plane in which the drug is delivered, changes to the rate of delivery, and changes in the 351 consistency of the combination product?
|
Changes in delivery include changes in the tissue 349 plane in which the drug is delivered, changes to the rate of delivery (because of 350 change in injection time between the PFS and autoinjector), and changes in the 351 consistency of the PK 348 profile
|
What is the pref What is the pref What is the pref What is the pref What is the pref What is the pref What is the pref What is the pref What is the pref What is the pref What is the pref Who should not be able to modify the documents or security measures used to track electronic record changes?
|
personnel who create, modify, or delete electronic records
|
What should describe when, by whom, and the reason changes were made to the electronic record?
|
Audit trails
|
What should be notified if a system date or time discrepancy is detected?
|
authorized personnel
|
What is the most likely use of computerized systems?
|
multi-center clinical trials
|
What should be put in place to ensure that access to the computerized system and to the data is restricted to authorized personnel?
|
external safeguards
|
What should be kept in the study documentation, accessible for use by appropriate study personnel and for inspection by FDA investigators?
|
That record should be kept in the study documentation
|
What is the main effect of computer viruses and worms on study data and software?
|
harmful software code
|
What should you do to avoid falsification of data?
|
perform a careful analysis
|
What should FDA describe and explain how source data were obtained and managed?
|
how electronic records were used to capture data
|
What should be retained as part of the study records and be available for inspection by FDA?
|
this documentation
|
What will the extent to which existing safety data or 352 effectiveness data can be bridged and leveraged depend on?
|
PK comparisons
|
What should be regularly backed up in a procedure that would prevent a catastrophic loss and ensure the quality and integrity of the data?
|
a procedure
|
What should be evaluated and some should be validated depending on risk?
|
Changes that exceed previously establishes
|
What should be documented?
|
all changes to the system
|
What should be documented for the purpose of this guidance?
|
computer education, training, and experience
|
What is a process that captures details such as additions, deletions, or alterations of information in an electronic record without obliterating the original record.?
| null |
What is a computerized system used for?
|
create, modify, maintain, archive, retrieve, or transmit in digital form information related to the conduct of a clinical trial
|
What are the values that represent the first recording of study data?
|
original data
|
What are some of the sources of original records?
|
hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation checklists
|
What is the purpose of a Transmit?
|
to transfer data within or among clinical study sites, contract research organizations, data management centers, sponsors, or to FDA
|
What is the FDA's Compliance Program Guidance Manual?
|
Compliance Program 7348.811 - Bioresearch Monitoring - Clinical Investigators
|
What is the design verification ensur?
|
Design validation ensur
|
What is the FDA's Part 11 of Electronic Records?
|
Electronic Records; Electronic Signatures — Scope and Application
|
What should the SOPs include, but are not limited to, the following processes?
|
The SOPs
|
What is the Guidance for the Content of Investigational Device Exemptions for Solutions for Hypothermic Flushing, Transport and Storage of Organs for Transplantation?
|
Guidance for the Content of Investigational Device Exemptions for Solutions for Hypothermic Flushing, Transport and Storage of Organs for Transplantation
|
What is the branch of Reproductive Abdominal and Radiological Devices that handles Renal Devices?
|
Division of Reproductive Abdominal and Radiological Devices Office of Device Evaluation Preface Public Comment Comments and suggestions may be submitted at any time for Agency consideration to Dockets Management Branch, Division of Management Systems and Policy, Office of Human Reso Answer: Answer: Answer: Answer: Answer: Answer: Answer: Answer: Answer: FDA Reviewers Document issued on January 16, 2001 U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Gastroenterology and Renal Devices Branch Division of Reproductive Abdominal and Radiological Devices Office of Device Evaluation Preface Public Comment Comments and suggestions may be submitted at any
|
What is the name of the room in the Food and Drug Administration's guidance document?
|
Room 1061
|
What is the name of the telephone number that CDRH uses to send documents via fax?
|
301-827-0111
|
What is the pound sign for the nt number 1164?
|
pound
|
What is the Code of Federal Regulations?
|
Code of Federal Regulations
|
What is the name of the FDA's guidance document regarding IDEs?
|
Investorigational Device Exemptions Manual
|
What does this document not address?
|
preservation of the cornea
|
What is the name of the guidance for industry and FDA staff Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products?
|
Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products
|
What do we believe need to be addressed before your device can be approved for marketing?
|
issues identified in this guidance document
|
What is the least burdensome approach to resolving the issues presented in the guidance document?
|
we believe that we have considered the least burdensome approach
|
What is the FDA's recommendation for all IDEs for these products?
|
contain the information described on the following pages
|
What should be provided to demonstrate that the chemicals possess sufficient purity for use in this product?
|
adequate justification
|
What should be provided in lieu of biocompatibility testing?
|
Biological Evaluation of Medical Devices Part-1: Evaluation and Testing
|
What should be assessed after storage for specified time periods?
|
sterility (bacteria and endotoxin)
|
What will normally be necessary to demonstrate the safety of the solution and, possibly, to establish the appropriateness of surrogate endpoints that may be used in the clinical trial.?
| null |
What is the most important factor in selecting the animal model?
|
relevance to the ultimate clinical use of the product
|
What should the control be widely used for?
|
preservation of the organ in question
|
What do foreign sites not require?
|
IDE approval
|
What is the purpose of the concentration-time profile?
|
applicant intends to gather additional 359 information to evaluate clinical effect of these differences
|
What should be provided along with copies of all published or unpublished adverse information?
|
copies of all published or unpublished adverse information
|
What is the control solution currently in use at the investigational site?
|
heterogeneous control
|
What is the FDA's opinion on the use of trol?
|
The FDA believes that it would be appropriate to include data from at least one U.S. investigational site in the marketing application
|
How many sites should the study include?
|
4 at least three
|
What should be provided to the patient for removal from the study?
|
A complete listing of the inclusion/exclusion criteria
|
What is the primary endpoint of the study?
|
7 day graft survival
|
What are appropriate secondary endpoints for heart preservation solutions?
|
cardiac index, wedge pressure, need for inotropic drugs, biopsy results and time in ICU
|
What should be provided to FDA to discuss the issues of “extended” preservation time?
|
preservation times
|
What is the name of the Guidance for Clinical Trials of Non-Diagnostic Medical Devices?
| null |
What is the name of the Guidance for Industry and Food and Drug Administration Staff Addition of URLs to Electronic Product Labeling Document issued on: September 30 Guidance for Industry and Food and Drug Administration Staff?
| null |
What is the name of the branch of the Agency that provides electronic products?
|
Electronic Products Branch
|
What did the applicant not intend to modify?
|
device performance specifications
|
What is the address of the Division of Dockets Management?
|
5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD, 20852
|
What is the document number for guidance for Industry and Food and Drug Administration Staff?
|
1703
|
What is the FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA issuing t Answer: FDA?
| null |
What does 21 CFR 1010.3(a)(1) and (2) require manufacturers to include on their electronic product labels?
|
full name and address and place, month and year of manufacture
|
What does FDA's guidance documents do not establish?
|
legally enforceable responsibilities
|
What is the month and year of manufacture on a product's identification tag or label?
|
21 CFR 1010.3(a)(1) and (2)
|
What does CDRH not recommend in instances where a manufacturer is unable to place its URL, in addition to the required full name and address and place, month and year of manufacture, on its current product label?
|
inclusion of the URL
|
What should a manufacturer point directly to when adding its URL to a product tag or label?
|
1. A web page where the manufacturer’s full name and current physical address are posted
|
What is one factor the Agency may consider in making such a determination?
|
The presence of the URL on the product label
|
What is the name of the organization that is responsible for the administration of the Ultrasound Stimulator System?
|
Food and Drug Administration Center for Devices and Radiological Health
|
What is the same in the route of administration?
|
the 374 same (subcutaneous)
|
What is the address of the Dockets Management Branch?
|
5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD, 20852
|
What is the name of the document that you are requesting?
|
1701
|
What is the name of the testing method used to determine the device's scope?
|
Scope
|
What is the acronym for Electrical and Mechanical Safety Performance Testing?
|
EMC
|
What is the name of the device that is used for aesthetic use?
|
Focused Ultrasound Stimulator System
|
What is the purpose of the focused ultrasound stimulator system?
|
for aesthetic use
|
What must a manufacturer who intends to market a device of this generic type conform to?
|
general controls of the Federal Food, Drug & Answer: (1) conform to the general controls of the Federal Food, Drug & Answer: evice
|
What is the FD&C Act?
|
21 CFR 807 Subpart E
|
What does the FDA identify and describe measures that if followed by manufacturers and combined with the Class II Special Controls Guidance Document general controls, will generally address the risks associated with focused ultrasound stimulator systems and lead to a timely 510(k) review?
| null |
What is a Focused Ultrasound Stimulator System for Aesthetic Use Identification?
|
a device using focused ultrasound to produce
|
What is the combination or bundle of multiple parallel detection schemes designed to detect?
|
one type of potential abnormality revealed in the patient radiological data
|
What was not changed by the modification of the autoinjector?
|
the user interface
|
What is the purpose of focused Ultrasound Stimulator System for Aesthetic Use?
|
Focused Ultrasound Stimulator System for Aesthetic Use
|
What do we recommend you identify within the scope of the 510(k)?
|
Device Components
|
What is the FDA's general view of evice and the predicate?
|
indications for use and technological characteristics
|
What should you do before submitting your premarket notification to identify other risks?
|
conduct a risk analysis
|
What should be demonstrated that the focused ultrasound stimulator system meets all design specification and performance requirements?
|
meets all design specification and performance requirements
|
What should be demonstrated by measurements of temperature distributions in vitro, such as in tissue mimicking materials, and via computational modeling of the thermal dose?
|
predictable thermal lesions
|
What should be addressed in testing to avoid cavitation and bubble formation?
|
possible cavitation and bubble formation either in the focal region or at the device-tissue interface
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.